trending Market Intelligence /marketintelligence/en/news-insights/trending/uTAz3fphD-kjTHd02fHQtw2 content esgSubNav
In This List

CTI BioPharma prices $45M preferred stock offering

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


CTI BioPharma prices $45M preferred stock offering

CTI BioPharma Corp. priced an underwritten public offering of 22,500 series N-3 preferred stock at $2,000 apiece to raise $45 million in gross proceeds.

The company had originally planned to issue the stock at $1,000 apiece. The stocks are convertible into common shares of the company at a rate of $3 apiece for a total of about 15 million common shares.

CTI plans to use the net proceeds to conduct its PAC203 clinical trial, submit a new marketing authorization application for pacritinib with the European Medicines Agency, conduct research for the possible application of pacritinib in indications other than myelofibrosis and complete its PIX306 clinical trial.

Jefferies LLC is acting as the sole book-running manager for the offering, while BTIG LLC is acting as its lead manager.

The offering is expected to close by June 9.